SIN3B and cancer: Overall, this data supports that SIN3A and SIN3B expression levels in cancer patients will depend on molecular subtype; and in triple negative breast cancer, lowered expression of SIN3A and higher expression of SIN3B may be associated with more aggressive disease progression.